INTRODUCTION
Primary sclerosing cholangitis (PSC) constitutes an unsolved medical burden with high mortality,
Significance of this study
What is already known on this subject?
▸ Pancreatic autoantibodies (anti-glycoprotein 2 (anti-GP2)/anti-CUB and zona pellucida-like domains 1) specifically identify patients with Crohn's disease with distinct complicated phenotypes. However, they display variableyet unsolved-presence in patients with UC. ▸ Preliminary data suggest that primary sclerosing cholangitis (PSC) is a common comorbidity among patients with anti-GP2-positive UC. ▸ Several autoantibodies are described in PSC.
However, their correlations to clinical parameters remain inconsistent. ▸ Interestingly, no single prognostic tool, biomarker or other sparsely present risk factors in the general PSC population are capable of estimating the risk for PSC-associated malignancies.
What are the new findings?
▸ The pancreatic autoantibody anti-GP2 IgA was frequently observed in large bile duct diseases from various origins (PSC, secondary sclerosing cholangitis, cholangiocarcinoma (CCA)). ▸ Anti-GP2 IgA positivity occurred in about 50% of patients with PSC independent of associated IBD and consistently identified distinct severe phenotypes in PSC. ▸ A meta-analysis across the cohorts yielded an OR of 5.0 of CCA in patients with anti-GP2 IgA-positive PSC. ▸ Anti-GP2 IgA identified patients with poor survival and harboured predictive potential for early death or liver transplantation (LTX) in two independent cohorts from Norway and Germany. This effect was primarily based on PSC-associated biliary tract cancer.
which is primarily based on the premalignant character of PSC. 1 Specifically, PSC-related cancer of the biliary tree is a major complication, among other, causing high mortality. 2 The progressive and destructive inflammation of the bile ducts in PSC requires liver transplantation in the majority of the patients after a median of 12-18 years. 3 In addition, up to 80% of patients with PSC are also affected by IBD, and vice versa, 4.0%-7.5% of patients with UC suffer from PSC, 4 conferring an increased risk for developing colorectal carcinoma. 5 However, the lifetime risk of patients with PSC for developing biliary tract cancer (cholangiocarcinoma (CCA), gallbladder cancer (GBC)) is estimated much higher with approximately 13%-14% or even up to 33% in some cohorts. 1 6 7 The current knowledge concerning risk factors for CCA in PSC is limited 1 3 5 and the evidence is insufficient to use these factors for stratifying the risk of patients with PSC, who are more likely to benefit from a screening programme.
Despite the combined use of modern diagnostic tools, many patients with PSC with biliary tract cancer are not diagnosed until an advanced stage. 1 8 CCA is found synchronously with the diagnosis of PSC in 20%-30% and within 1 year in 50%. 9 Identifying patients at risk for biliary tract cancer thus remains one of the major challenges with the surveillance programme.
Currently, no single prognostic tool is capable of estimating the risk in the individual patient. 5 10 Thus, there is a clear need for new biomarkers, providing information about the cancer risk and prognostic information for the decision of early and prioritised liver transplantation in PSC.
The aetiology of PSC, as well as IBD, remains elusive, though increasing evidence suggests autoimmune-mediated inflammation in both diseases. [11] [12] [13] In PSC, the presence of several autoantibodies is one of the features indicative of an autoimmune aetiology; however, no clear conclusions can be drawn from the literature regarding their correlation to clinical parameters or aetiological implications. 13 The co-occurrence and partly overlapping genetics of PSC and IBD, as well as frequently observed autoantibodies in both conditions (antineutrophil cytoplasmic antibody (ANCA) with perinuclear pattern ( p-ANCA)), suggest that common pathophysiological motifs could be relevant in PSC and IBD. Among others, we recently observed an association of the pancreatic autoantibody (PAB) against glycoprotein 2 (anti-GP2) with distinct phenotypes in Crohn's disease (CD) but with a low frequency in UC. 14 15 PABs, which additionally comprise antibodies against the complement subcomponents C1r/C1sC1s, Uegf, bone morphogenetic protein (CUB) and zona pellucidalike domains 1 (anti-CUZD1), also yielded prognostic information in IBD, specifically CD. 14 The use of PABs as additional biomarkers in IBD is supported by the observation that they may precede specific CD phenotypes (stricturing/perianal disease) and also function as stable disease markers. 14 15 Nevertheless, the functional implication of anti-GP2 positivity and the association with complicated disease phenotypes in CD remains elusive. 16 PABs are directed against proteins predominantly expressed in the exocrine pancreas, 17 18 the intestinal epithelium, 19 but-as GP2-are additionally present in different concentrations in the bile juice of patients with PSC with and without CCA. 20 Despite the interpretation of PABs as CD-specific markers, some studies also reported anti-GP2 seropositivity with variable prevalence in patients with UC. 21 Interestingly, we formerly identified a remarkable occurrence of anti-GP2 IgA in patients with IBD with concomitant PSC (three out of nine positive, 33%, data not published). Therefore, we now investigated an association of anti-GP2 with PSC in two larger and independent cohorts with a focus on concomitant IBD, clinical parameters and outcomes, including liver transplantation.
PATIENTS AND METHODS Study population
In the evaluation phase, 138 serum samples of patients with well-characterised large duct PSC (78% male) from the biobank of the Norwegian PSC Research Centre (Oslo University Hospital, Rikshospitalet) were assayed for PABs (anti-GP2 IgA and IgG/anti-CUZD1 IgA and IgG), see table 1. In addition, clinical biochemistry including liver enzymes was retrieved from clinical databases (see online supplementary table S1). Revised Mayo risk score (MRS) 22 and aspartate transaminase (AST)/ platelet relation index were determined for each Norwegian patient with PSC.
Norwegian PSC samples had been collected between the years 2008 and 2012 (median follow-up (range) 2.2 years (0.0-4.3) from serum sampling). In Heidelberg, the collection of PSC samples took place in the period from 2006 to 2015 (median follow-up (range) 3.5 years (0.0-8.83) from serum sampling). 23 During the observation period, dates of certain censor events like liver transplantation or occurrence of biliary tract cancer like CCA and GBC were well documented. All patients with PSC were screened clinically and endoscopically for concomitant IBD.
IBD was defined according to accepted criteria. 24 Subsequently, significant associations were validated in an independent German cohort (n=180, 68% male) at the Centre for Liver Transplantation in Heidelberg (University Hospital Heidelberg, Germany). In addition, we refer to a small cohort from Lübeck in the introduction (data not shown), which consisted of nine patients with IBD-related PSC. This cohort comprised 77.8% patients with UC and 22.2% patients with CD. One third of this cohort was male and mean age was 30.6 years (SD: 14) with a mean disease duration of 13.7 years (SD: 9).
The control groups consisted of 52 gender-matched and agematched healthy blood donors from the University Hospital of Oslo (Norway) as well as 62 patients with well-defined diagnosis of UC recruited at the University Hospital of Lübeck Significance of this study How might it impact on clinical practice in the foreseeable future?
▸ Anti-GP2 IgA can be hypothesised as a novel marker in large bile duct disease of various origins. ▸ In particular in PSC, anti-GP2 IgA has to be considered as a novel prognostic/diagnostic tool for PSC-associated CCA. Prospectively, it might serve as a complementary tool in established clinical scores (Model for End-Stage Liver Disease) with the aim of early prioritised LTX. ▸ The presence of a secretory IgA antibody against the bacteria-binding antigen GP2 opens new avenues for further studies on bacterial (infectious) triggers in PSC aetiology.
(Germany), see table 1. These patients with UC were included with respect to age and gender matching and subsequently analysed for the prevalence of PABs (anti-GP2, anti-CUZD1). Additional 56 patients with CCA without PSC, 20 patients with secondary sclerosing cholangitis (SSC) and 18 with autoimmune hepatitis (AIH) were included from the University hospitals Heidelberg and Oslo (table 1). The protocol was in accordance with the Declaration of Helsinki.
Antibody testing
Analysis of anti-GP2 and anti-CUZD1 was performed by indirect immunofluorescence (Euroimmun, Lübeck, Germany). A detailed description has been given previously. 15 For further information, please see online supplementary file.
Statistical analysis
We performed statistical analysis using IBM SPSS Statistics, V.22 (SPSS, Chicago, Illinois, USA) and GraphPad Prism V.5.00 for Windows, GraphPad Software, San Diego, California, USA.
To test for normal distribution, the Kolmogorov-Smirnov test was used. Non-normally distributed data are indicated with median and quartiles as measures of central tendencies. For normally distributed data, mean and SD are used. Relative frequencies (in per cent) refer to the number of cases without missing data.
For contingency analysis, the χ 2 -independence test was applied. Comparison of continuous variables was performed using the Mann-Whitney U test or t test, depending on data distribution. The level of significance was set at 0.05. Logistic and linear regression models were performed to test for independency of the detected associations from potential clinical confounders (eg, disease duration, gender, age, concomitant IBD). Survival curves were created according to the Kaplan-Meier method. Log-Rank test was applied for comparison of survival distribution. To further evaluate a combination of potential prognostic factors, a Cox Proportional Hazard model was given in a last step. The Cox model was used with a force inclusion strategy as well as with the forward inclusion and backward exclusion methods.
For meta-analysis of both cohorts in terms of biliary tract cancer, the Cochran-Mantel-Haenszel test was used. Heterogeneity of the ORs was assessed with the Breslow-Day test.
RESULTS
High prevalence of anti-GP2 in PSC and significant occurrence in other biliary large duct diseases As shown in table 1, the Norwegian and German patients with PSC were similar as evaluated by age at serum sampling (41.4 vs 40.7 years), gender (77.5% vs 67.4% males) and prevalence of concomitant IBD (74.5% vs 69.4%, respectively) and subtypes of IBD. We observed a high prevalence of anti-GP2 IgA in Norwegian patients with PSC (n=71, 52%) compared with healthy control (HC) (n=1, 1.9%) (p<0.001, OR=55.7, table 1).
Prevalent anti-GP2 IgA positivity (n=84, 46.7%) was confirmed in an independent German PSC cohort.
As depicted in table 1, the anti-GP2 IgA prevalence in UC without PSC was at the level of HC ( p=0.9).
A significant anti-GP2 IgA occurrence was also detected in both benign and malignant biliary large duct disease controls but not in AIH (table 1) .
Clinical parameters of patients with anti-GP2 IgA-positive PSC differed significantly from anti-GP2 IgA-negative patients
We next analysed clinical characteristics of the Norwegian and German patients with PSC according to their anti-GP2 IgA status (table 2) . Median disease duration at the time of blood collection was numerically increased in anti-GP2 IgA-positive patients in both cohorts (Norway: 0.94 vs 2.78 years, respectively and Germany: 5.33 vs 7.04 years, respectively), but the differences were only statistically significant in the Norwegian cohorts (table 2) . Additionally, a marked prevalence of patients with short disease duration ≤1 year was already positive for anti-GP2 IgA (Norwegian cohort: 46.9% and German cohort: 34.2%, respectively). Age at diagnosis was similar in anti-GP2 IgA-positive and negative patients in the Norwegian cohort, while anti-GP2 IgA-positive patients were younger in the German cohort (table 2) .
In both cohorts, the prevalence of anti-GP2 IgA was similar irrespective of the presence of IBD, 52% versus 54% in the Norwegians and 49% versus 42% in the Germans (table 2) . There were also no significant differences regarding the IBD subtypes observed. In contrast, multiple measures indicated more severe disease in anti-GP2 IgA-positive than negative PSC patients (table 2 and see online supplementary table S1 ). In particular, increased MRS was observed in anti-GP2 IgA-positive compared with negative PSC patients in both the Norwegian and German cohort ( p<0.001).
Additionally, anti-GP2 IgA titres correlated with disease severity (see online supplementary figures S1 and S2) as indicated by correlation analysis for anti-GP2 IgA with serum bilirubin (Spearman's r (bilirubin) =0.493, p<0.001) and the MRS (Spearman's r (MRS) =0.499, p<0.001).
Similar associations between anti-GP2 IgA positivity and biochemical markers of a more pronounced biliary duct inflammation were observed in CCA as well as in SSC (see online supplementary tables S2 and S3).
Association of anti-GP2 IgA with CCA
A strong association was observed between anti-GP2 IgA positivity and biliary tract cancer (CCA and GBC) in the Norwegian cohort; 19.7% of the anti-GP2 IgA-positive patients developed CCA and 4.2% developed GBC, compared with 3.1% (CCA) and 0% (GBC) of the anti-GP2 IgA-negative patients, (p<0.001 for both comparisons, table 1). When analysing the German cohort, only the association with CCA was validated; 13.1% of the anti-GP2 IgA-positive patients developed CCA compared with 4.2% of the anti-GP2 IgA-negative patients (p=0.031, table 2).
Overall, more than 86% of the PSC-associated CCA's were anti-GP2 IgA positive (table 2) compared with 35.7% anti-GP2 IgA positivity in CCA without PSC (p<0.001).
Notably, multivariate logistic regression analyses demonstrated an independent association of anti-GP2 IgA ( p=0.045/ p=0.042) with CCA irrespective of bilirubin, age and PSC duration in both cohorts (table 3) .
Differences in anti-GP2 IgA titres between patients with PSC with or without biliary tract cancer were not detected (Norwegian cohort: p=0.55; German cohort: p=0.95).
A meta-analysis across the cohorts yielded an OR of CCA in anti-GP2 IgA positive of 5.0 in all patients with PSC (95% CI 2.0 to 12.7, p<0.001), with no heterogeneity of the ORs observed between the cohorts ( p=0.378). With respect to the correlation between anti-GP2 IgA and markers of disease severity, the association of anti-GP2 IgA and CCA in both cohorts was retested under exclusion of all patients with more than just a slight increase in bilirubin (>51.3 mmol/L).
Though the cases of CCA, which were included for analysis, consequently more than halved in both cohorts a meta-analysis still revealed an OR of CCA in anti-GP2 IgA + of 2.0 in all patients with PSC (95% CI 0.7 to 5.8, p=0.225).
Patients with anti-GP2 IgA-positive PSC exhibited poorer cumulative survival rates
The influence of anti-GP2 IgA on liver transplantation-free survival in PSC was analysed during a 4-year, respectively 10-year, observation period. Anti-GP2 IgA positivity was associated with shorter liver transplantation-free survival in both the Norwegian and German cohort, as analysed by the Kaplan-Meier plot ( p=0.016 and p=0.018, respectively), see figure 1A , B.
When categorising the patients with PSC according to anti-GP2 IgA titre: negative (<1:10), low (titres from 1:10 to 1:99) and high (1:100 or above), the survival was reduced in the groups with high anti-GP2 IgA titre ( figure 1C, D) .
Consequently, univariate Cox regressions revealed high anti-GP2 IgA titre as a predictor for poor survival rates in both cohorts (HR=2.4, (95% CI 1.3 to 4.6), p=0.006 in the Norwegian cohort and HR=2.6 (95% CI 1.37 to 5.02), p=0.004 in the German cohort).
No influence on survival could have been observed based on anti-CUZD1 IgA positivity (see online supplementary figure S3 ). The poor survival in the anti-GP2 IgA-positive Norwegian and German patients could in part be explained by an increased frequency of biliary tract cancer. However, both cohorts showed trends towards reduced liver transplantation free survival in anti-GP2 IgA-positive individuals also when patients developing biliary tract cancer (CCA or GBC) were removed from the analysis ( p=0.34 and p=0.055, respectively; see figure 2A, B) . When analysing only patients with death as an endpoint (ie, removing patients receiving Figure 1 Kaplan-Meier survival curves for patients with primary sclerosing cholangitis (PSC), depending on anti-GP2 IgA status or titre during a 4-year, respectively 10-year, observation period. (A) Survival curves significantly differed between anti-GP2 IgA-positive and negative Norwegian patients with PSC during a 4-year observation period ( p=0.016, Log Rank). In detail: mean survival of anti-GP2 IgA-positive patients was 2.5 years (SEM=0.20; (95% CI 2.1 to 2.9)). Mean survival of anti-GP2 IgA-negative patients was 3.2 years (SEM=0.17; (95% CI 2.9 to 3.6)). (B) Survival curves significantly differed between anti-GP2 IgA-positive and negative German patients with PSC during a 10-year observation period ( p=0.039, Log Rank). In detail: mean survival of anti-GP2 IgA-positive patients was 5.2 years (SEM=0.36; (95% CI 4.5 to 5.9)). Mean survival of anti-GP2 IgA-negative patients was 6.4 years (SEM=0.4; (95% CI 5.6 to 7.2)). (C and D) Patients with PSC were categorised in three groups: anti-GP2 IgA negative (<1:10), low (titres from 1:10 to 1:99) and high (1:100 or above). Survival curves significantly differed ( p=0.013, Log Rank and p=0.005, Log Rank). Moreover, high anti-GP2 IgA titre was associated with reduced survival in a univariate Cox regression model for both cohorts ( p=0.006 and p=0.004). GP2, glycoprotein 2. liver transplant), there was a similar reduced survival in anti-GP2 IgA-positive patients ( p=0.021 in the Norwegian cohort, p=0.069 in the German cohort, see online supplementary figure S4) .
To test the predictive potential of anti-GP2 IgA on liver transplantation-free survival in PSC, a multivariate Cox regression analysis was performed, including anti-GP2 IgA, MRS and disease duration. In this multivariate Cox regression, only the MRS remained independently associated with outcome, whereas anti-GP2 IgA was not significant (Norwegian cohort: p=0.353 (anti-GP2 IgA); p<0.001 (MRS); p=0.877 (disease duration)), with comparable results in the German cohort (German cohort: p=0.258 (anti-GP2 IgA); p<0.001 (MRS); p=0.339 (disease duration)).
Further exploration of the data showed that anti-GP2 IgA positivity remained a significant predictor for poor survival ( p=0.021) in multivariate Cox regression in the German cohort, when MRS was subdivided into three categories with p values of <0.001 (low MRS), p=0.304 (intermediate MRS) and <0.001 (high MRS), while this was not the case in the Norwegian cohort, subdividing the MRS into three categories had no effect on the significance of anti-GP2 IgA ( p=0.94).
DISCUSSION
In this first study of anti-GP2 autoantibodies in PSC, anti-GP2 IgA was detected in about half the patients in two independent cohorts. Anti-GP2 IgA was consistently associated with reduced transplantation-free survival and a high frequency of CCA. Moreover, the association of anti-GP2 IgA with CCA in PSC was independent of other CCA risk factors in PSC such as duration of disease, higher age at diagnosis and serum bilirubin, indicating that anti-GP2 identified patients with a distinct, more severe, disease phenotype.
The only serological marker in PSC with a similar prevalence as anti-GP2 IgA is p-ANCA, which has been observed in the range of 26%-94% of patients with PSC. 13 Although some studies have reported associations between p-ANCA and IBD status, biliary tract complications and disease stage, [25] [26] [27] [28] no consistent clinical correlations have been observed with ANCA across the more than 20 studies performed. 13 In the present study, anti-GP2 IgA correlated with biochemical markers of disease activity and was associated with reduced transplantationfree survival based on increased prevalence of CCA in anti-GP2 IgA positives, irrespective of the CCA risk factors mentioned above 1-3 5 and irrespective of the MRS. Notably, anti-GP2 IgA seems to be present early in the disease, as shown by a high frequency in patients with a short duration (≤1 year) of PSC (46.9%).
CCA is a major challenge in PSC with limited diagnostic and therapeutic options and although more than half of the cases occur in the first year after diagnosis of PSC 9 the subsequent risk increases with disease duration. 2 During later follow-up, the yearly developmental rate of CCA is 0.5%-1.5%. 7 Therefore, better opportunities for an early diagnosis and new prognostic tools for risk stratification are extremely important.
Still, CCA in PSC is often diagnosed in advanced stages. 1 8 In this regard, the optimal time for liver transplantation is intensively discussed. 29 Anti-GP2 IgA may therefore be additionally useful as a tool to identify patients with increased risk for biliary cancer warranting intensified follow-up. Although anti-GP2 IgA was not an independent predictor of transplantation-free survival when including MRS in multivariate Cox regression analysis of the Norwegian cohort, anti-GP2 IgA was independently associated with CCA in both cohorts.
Hence, further prospective studies should re-evaluate anti-GP2 IgA as an independent predictor for CCA and survival in PSC. Such studies may also clarify, whether anti-GP2 IgA is associated with CCA and with the observed poor non-cancer-related survival in PSC.
Anti-GP2 cannot be considered specific for PSC since anti-GP2 autoantibodies also occur in other diseases such as CD. 17 Notably, the presence of anti-GP2 of the IgA type in about 50% of the patients with PSC is higher than that observed in CD (3.4%-24%), in which IgG subclasses regularly predominate, and a lot higher than in UC and HCs, where it is virtually absent (0%-2.9%). 14-16 30 Regarding IBD in PSC, this is most often classified as UC, although certain clinical characteristics (including right-sided dominance, backwash ileitis, rectal sparing) suggest that UC-related PSC could represent a third IBD type. 31 32 This may explain the similar frequency of anti-GP2 IgA in patients with PSC with UC and CD observed in both the patient panels in the present study. The observation that anti-GP2 IgA also had a similar prevalence in patients without concomitant IBD suggests that anti-GP2 is primarily related to the manifestation of the disease process in the bile ducts and not the intestine. Indeed, we also observed anti-GP2 IgA positivity in other large duct diseases such as CCA without PSC and SSC but not in AIH, and in particular in association with elevated liver biochemistry, suggesting that it may be a marker of severe cholestatic liver disease. Consequently, reservation is justified whether anti-GP2 IgA may be implicated in the aetiopathogenesis of PSC, although it is so far unknown to what degree sclerosing cholangitis is a disease-specific phenomenon or a final common pathway of different aetiologies.
Nevertheless, the consistent identification of a distinct severe phenotype in PSC based on an autoantibody, which is even present in half of patients with short duration PSC and which is, at least in IBD, known to be very stable over the disease course, 14 15 points towards a novel, urgently needed, diagnostic potential in PSC.
Furthermore, the independent association of anti-GP2 IgA with CCA and the consistent association with poor survival together with the observation that GP2 protein levels are reduced in the bile of patients with PSC with CCA 20 suggest a pathophysiological function of these anti-GP2 antibodies with biliary GP2 function. Substantial evidence demonstrates that the antigen GP2 exerts bacteria-binding properties in the intestinal lumen, 33 34 and it was suggested that GP2 is centrally involved in the development of antigen-specific mucosal immune responses against gut bacteria. 33 Considering that key elements of PSC aetiology include infectious triggers 11 or toxic/immunological effects of bile acids, 35 the autoantibody anti-GP2 could reflect a shared autoimmune mechanism of PSC and IBD.
The major strength of the present study is the inclusion of two large and well-characterised PSC cohorts from Norway and Germany to validate a preliminary observation in a small number of patients with UC. It should be kept in mind that the cohorts were recruited from tertiary care centres, although patients with PSC at all stages were included. The retrospective character of the study restricts the predictive significance of the survival analysis depending on anti-GP2 IgA. Therefore, further prospective studies with distinct clinical endpoints are warranted to decipher the exact predictive potential of anti-GP2 IgA in PSC.
In conclusion, anti-GP2 IgA identifies patients with PSC with severe phenotypes independent from concomitant IBD. The association with poor survival in two independent European cohorts in part due to CCA highlights promising characteristics of anti-GP2 IgA as a novel prognostic tool in the risk stratification of patients with PSC. Further studies are warranted to accurately define the clinical utility of anti-GP2 IgA as a predictive biomarker in PSC. Moreover, the association of anti-GP2 IgA with PSC and PSC-related cancer opens new avenues for further studies of GP2 function in the biliary tree.
